US Sustiva Oral Liquid Expanded Access Program: an Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266).

Trial Profile

US Sustiva Oral Liquid Expanded Access Program: an Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266).

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Efavirenz (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Jan 2014 Status changed from recruiting to completed as ClinicalTrials.gov reports expanded access is no longer available for this treatment.
    • 14 May 2008 The expected completion date for this trial has changed from Sep 2009 to Dec 2010 according to ClinicalTrials.gov
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top